MetaCap

Citius Pharmaceuticals (CTXR) vs Neuphoria Therapeutics (NEUP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Neuphoria Therapeutics (NEUP) has outperformed Citius Pharmaceuticals (CTXR) over the past year, losing 47.3% versus a loss of 55.4%. Citius Pharmaceuticals is the larger company by market cap ($14.0 million vs $12.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTXR-55.39%NEUP-47.31%
+31%-21%-72%
Nov 21, 20251 yearNov 20, 2026
CTXR-98.70%NEUP-98.49%
+26%-39%-105%
Dec 13, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTXR versus NEUP key metrics
MetricCTXRNEUP
Share price$0.5085$2.35
Market cap$13.96M$12.72M
1-day change+2.27%+1.29%
YTD return-34.56%-39.43%
1-year return-55.39%-47.31%
5-year return-98.79%—
EPS (TTM)$-1.75$-2.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.17M
Revenue growth (YoY)—-92.50%
Net income (latest FY)$-39.74M$-13.45M
Operating margin—-1401.09%
Net margin—-1145.66%
52-week high$1.54$5.53
52-week low$0.37$2.26
Distance from 52-week high-66.98%-57.50%
Analyst consensusnonenone
Avg. price target upside+686.63%—
Average volume275.44K26.53K
Shares outstanding27.45M5.41M
Employees231
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Citius Pharmaceuticals

CTXR stock →

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About Neuphoria Therapeutics

NEUP stock →

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

CTXR vs NEUP FAQ

Which is bigger, Citius Pharmaceuticals or Neuphoria Therapeutics?

Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.96M compared with $12.72M for Neuphoria Therapeutics (NEUP).

Which stock has performed better over the past year, CTXR or NEUP?

NEUP returned -47.31% over the past 12 months, compared with -55.39% for CTXR (price return, excluding dividends). Past performance does not predict future results.

Are Citius Pharmaceuticals and Neuphoria Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons